Source: http://www.google.com/patents/US5523004?dq=552685
Timestamp: 2014-12-28 22:03:23
Document Index: 3840763

Matched Legal Cases: ['art 141', 'arts 131', 'art 131', 'art 131', 'art 131', 'art 131', 'art 131', 'arts 531']

Patent US5523004 - Method for treatment of blood using a blood bag - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inAdvanced Patent SearchPatentsA composite of interconnected bags comprises a blood collecting bag, a preserving liquid bag, and a blood plasma bag. The interior of the bag body of the blood collecting bag is divided by a partition strip into an empty space and an empty space of the shape of a strip, with the two empty spaces mutually...http://www.google.com/patents/US5523004?utm_source=gb-gplus-sharePatent US5523004 - Method for treatment of blood using a blood bagAdvanced Patent SearchPublication numberUS5523004 APublication typeGrantApplication numberUS 08/160,829Publication dateJun 4, 1996Filing dateDec 3, 1993Priority dateDec 4, 1992Fee statusPaidAlso published asDE69313412D1, DE69313412T2, EP0600804A1, EP0600804B1Publication number08160829, 160829, US 5523004 A, US 5523004A, US-A-5523004, US5523004 A, US5523004AInventorsNobukazu Tanokura, Yukihiro Ohnaka, Noboru IshidaOriginal AssigneeTerumo Kabushiki KaishaExport CitationBiBTeX, EndNote, RefManPatent Citations (18), Referenced by (18), Classifications (14), Legal Events (5) External Links: USPTO, USPTO Assignment, EspacenetMethod for treatment of blood using a blood bagUS 5523004 AAbstract A composite of interconnected bags comprises a blood collecting bag, a preserving liquid bag, and a blood plasma bag. The interior of the bag body of the blood collecting bag is divided by a partition strip into an empty space and an empty space of the shape of a strip, with the two empty spaces mutually communicating near the end part of the partition strip. The blood collected in the blood collecting bag is centrifuged. The upper layer of blood plasma resulting from the centrifugation is discharged via a tube to the blood plasma bag. Then, the erythrocyte preserving liquid in the preserving liquid bag is advanced through the tube, the empty space, and a connecting part and added upwardly from below to the concentrated erythrocyte left behind the empty space. The erythrocyte preserving liquid, without being stirred, is allowed to ascend and mingle with the concentrated erythrocyte with the elapse of time. Thus, the present invention provides a erythrocyte preparation excellent in quality and fee from occurrence of floccules.
What is claimed is: 1. A method for the treatment of blood by the use of a blood bag comprising a pouchy bag body for storing blood, a partition strip extended inside said bag body from one end part to the other end part of said bag body, and first and second tubes connected to one end part of said bag body as opposed to each other across said partition strip, with the interior of said bag body partitioned by said partition strip into at least two empty spaces communicating with each other near the other end part of said partition strip, which method comprises centrifuging the blood collected in said blood bag with one end part of said bag body held on the upper side thereby separating the blood into an upper layer of blood plasma and a lower layer of concentrated erythrocytes, discharging said blood plasma to the exterior of said bag body via said first tube, and then transferring a erythrocyte preserving liquid having a lower specific gravity than erythrocytes to the interior of said bag body upwardly from the lower side thereof such that said erythrocyte preserving liquid ascends the mass of said concentrated erythrocytes; and wherein said erythrocytes gradually descend the mass of said erythrocyte preserving liquid such that said erythrocyte preserving liquid and said erythrocytes become mixed.
SUMMARY OF THE INVENTION These objects can be attained by the present invention of the following (1). Further, the following (2) to (15) are preferable
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a plan view illustrating an embodiment of the construction of a blood bag to be used for this invention.
EXPLANATION OF THE PREFERRED EMBODIMENT In the method of this invention for the treatment of blood, since the erythrocyte preserving liquid is added to the blood bag upwardly from the lower side thereof unlike the conventional method which makes this addition downwardly from the upper part of the blood bag, the erythrocyte preserving liquid which has a lower specific gravity than the erythrocyte ascends the mass of erythrocyte while diffusing therein and the erythrocyte of a higher specific gravity gradually descend the mass of the erythrocyte preserving liquid. Thus, the erythrocyte preserving liquid and the erythrocyte is thoroughly stirred naturally without requiring any special treatment.
TABLE 1______________________________________Anticoagu-lant agent Components (g/100 ml � 100)______________________________________ACD-A      Sodium citrate   2.20 W/V %liquid     Citric acid      0.80 W/V %      Glucose          2.20 W/V %CPD liquid Sodium citrate   2.63 W/V %      Citric acid      0.327 W/V %      Glucose          2.32 W/V %      Monosodium phosphate                       0.251 W/V %CPDA-1     Sodium citrate   2.63 W/V %liquid     Citric acid      0.327 W/V %      Glucose          2.9 W/V %      Monosodium phosphate                       0.251 W/V %      Adenine          0.0275 W/V %Heparin    Sodium chloride  0.9 W/V %      Heparin sodium   500 U/15 ml______________________________________
TABLE 2______________________________________Erythrocytepreservingliquid      Components (g/100 ml � 100)______________________________________S.A.G.M.    Sodium chloride  0.877 W/V %liquid      Adenine          0.17 W/V %       Glucose monohydrate                        0.900 W/V %       Mannitol         0.525 W/V %OPTISOL     Sodium chloride  0.900 W/V %liquid      Adenine          0.27 W/V %       Glucose monohydrate                        2.000 W/V %       Mannitol         0.750 W/V %ADSOL       Sodium chloride  0.877 W/V %liquid      Adenine          0.30 W/V %       Glucose monohydrate                        0.900 W/V %       Mannitol         0.525 W/V %MAP liquid  Sodium chloride  0.552 W/V %       Adenine          0.016 W/V %       Glucose (anhydrous)                        0.801 W/V %       Mannitol         1.619 W/V %       Citric acid      0.022 W/V %       Sodium citrate   0.167 W/V %       Monnosodium phosphate                        0.104 W/V %______________________________________
EXAMPLE 1 A composite of interconnected bags constructed as shown in FIG. 1 was produced by preparing a blood collecting bag, a preserving liquid bag, and a blood plasma bag satisfying the conditions shown below and interconnecting these bags with tubes (having an inside diameter, c, of 3 mm) made of flexible polyvinyl chloride. As the erythrocyte preserving liquid, 90 ml of the MAP liquid was sealed in the preserving liquid bag. Experiment 1 which is shown below was performed on the composite of interconnected bags, with the erythrocyte preserving liquid introduced via the empty space 14A and the connecting part 141 into the empty space 14B and added upwardly to the concentrated erythrocyte in the empty space 14B of the blood collecting bag from below.
EXPERIMENT 1 A given composite of interconnected bags was subjected to sterilization with high-pressure steam. In the blood collecting bag, 56 ml of the CPD liquid (having the composition shown in Table 1) was placed as an anticoagulant agent. By means of a blood collecting needle, 400 ml of whole human blood was collected in the blood collecting bag. The composite containing the collected blood in the blood collecting bag was centrifuged with a centrifugal separating device (produced by Hitachi Koki Co., LtD. and marketed under product code of "CR-7B3) under the conditions of 3,300 G and 6 minutes.
The blood collecting bag which contained the concentrated erythrocyte incorporating therein the added erythrocyte preserving liquid was left standing in a refrigerator at 4� C. without stirring the erythrocyte. At the end of one week's standing in the refrigerator, the blood collecting bag was visually examined to determine whether or not the content thereof had formed floccules. The results are shown in Table 3.
EXAMPLE 2 A composite of interconnected bags constructed as shown in FIG. 9 was manufactured by connecting a blood collecting bag, a preserving liquid bag, a blood plasma bag, and a buffy coat bag satisfying the following conditions with tubes (inside diameter c=3 mm) made of flexible polyvinyl chloride.
CONTROL 2 A composite of interconnected bags constructed as shown in FIG. 12 was manufactured by connecting a blood collecting bag devoid of a partition strip, a preserving liquid bag, a blood plasma bag, and a buffy coat bag with tubes (inside diameter c=3 mm) made of flexible polyvinyl chloride.
EXPERIMENT 2 A given composite of interconnected bags was subjected to sterilization with high-pressure steam. Then, in the blood collecting bag, 56 ml of the CPD liquid (having the composition shown in Table 1) was placed as an anticoagulant agent. By means of a blood collecting needle, 400 ml of whole human blood was collected in the blood collecting bag. The composite containing the collected blood in the blood collecting bag was centrifuged with a centrifugal separating device (produced by Hitachi Koki Co., Ltd. and marketed under product code of "CR-7B3) under the conditions of 3,300 G and 6 minutes.
Then, the blood collecting bag which contained the concentrated erythrocyte incorporated therein the added erythrocyte preserving liquid was left standing in a refrigerator at 4� C. without stirring the concentrated erythrocyte. After one week's standing in the refrigerator, the blood collecting bag was visually examined to determine whether or not the content of the bag had formed floccules. The results are shown in Table 3.
EXAMPLE 3 A composite of interconnected bags similar to that of Example 1 was manufactured by following the procedure of Example 1, except that the partition strip of the blood collecting bag was fabricated as follows instead.
EXAMPLE 4 Composites of interconnected bags similar to those of Examples 1 and 3 were produced by following the respective procedures, except that a blood collecting bag was constructed (the partition strips disposed symmetrically right to left) as shown in FIG. 5. The widths of the partition strips and the positions and shapes of the end parts 131 were identical with those of Examples 1 and 3. The empty spaces 55B and 55C were identical with the empty space 14B of Example 1.
EXAMPLE 5 Composites of interconnected bags similar to those of Example 1 and 3 were produced by following respectively the procedures of Examples 1 and 3, except that blood collecting bags thereof were identical in construction with the blood collecting bag shown in FIG. 6 (the partition strips disposed symmetrically right to left). The width of the empty space 75A was 10 mm and the inner volume of the empty space 75A was about 1.6% of the total inner volume (about 456 ml) of the empty space 75B and the empty space 75B.
EXAMPLE 6 A composite of interconnected bags constructed as shown in FIG. 1 was produced by preparing a blood collecting bag, a preserving liquid bag, and a blood plasma bag satisfying the conditions shown below and interconnecting these bags with tubes (having an inside diameter, c, of 3 mm) made of flexible polyvinyl chloride.
EXAMPLE 7 A composite of interconnected bags constructed as shown in FIG. 1 was produced by preparing a blood collecting bag, a preserving liquid bag, and a blood plasma bag satisfying the conditions shown below and interconnecting these bags with tubes (having an inside diameter, c, of 3 mm) made of flexible polyvinyl chloride.
CONTROL 3 A similar composite of interconnected bags to that of Example 6 was manufactured, except that a BAT bag in which a tube for discharging plasmas was connected with the upper portion of the bag body as the blood collecting bag and a tube for introducing blood and a tube for discharging erythrocyte were parallelly connected with the lower end portion of the bag body.
EXPERIMENT 3 1. Separation rate of human false blood
EXPERIMENT 4 After collecting the separated components of human whole blood in Experiment 3, tubes connected with each bags are closed and cut. Then, buffy coat (BC) and concentrated erythrocyte (CRC) collected respectively to the blood collecting bag and erythrocyte bag were subjected to analysis, number of cells was determined and recovery ratio and removal ratio of each cells were obtained. Recovery ratio of erythrocyte (RBC) in concentrated erythrocyte (CRC), removal ratio of leukocyte (WBC) in concentrated erythrocyte, and recovery ratio of platelet (PLT) in buffy coat (BC) are shown respectively in FIG. 14, FIG. 15 and FIG. 16.
EXAMPLE 8 A similar composite of interconnected bags to Example 6 was manufactured, except that width H of the partition strip 13 (part other than end part 131) was 3 mm, minimum width a of the strip empty space 14B was 10 mm (a/f=0.153), shape of the end part 131 of the partition strip was zero shape as shown in FIG. 1 and curvature R were 2.25 mm (0.75H), 3.0 mm (1.0H) and 4.5 mm (1.5H) respectively.
CONTROL 5 A similar composite of interconnected bags to Example 6 was manufactured, except that the shape of the end part 131 of the partition strip 13 was a half circled shape having 1.5 mm (0.5H) of the curvature.
CONTROL 6 A similar composite of interconnected bags to Example 6 was manufactured, except that the shape of the end part 131 of the partition strip 13 was cut shape.
EXPERIMENT 5 The following severe tests were carried out about each blood collecting bags in Example 8 and Controls 5 and 6.
EXAMPLE 9 The same experiments were carried out as in Experiments 3 to 5 except that the position of the end part 131 of the partition 13 to the position Z in FIG. 2 and similar bags to Examples 6 and were manufacture to obtain approximately the same results respectively.
EXAMPLE 10 A similar composite of interconnected bags to those of Examples 6 and 8 was manufactured except that the construction of the blood collecting bag is as shown in FIG. 5 (arrangement of the partition strip is symmetrical). Further, in the blood collecting bag, a position of the end parts 531 and 541 of both partition parts were a position corresponding to Y in FIG. 2, and the empty spaces 55B and 55C were similar to the empty space 14B shown in Example 6. The same experiments as Experiments 3 to 5 were carried out about each composite interconnected bags to obtain approximately the same results respectively.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS3304977 *Jan 11, 1965Feb 21, 1967Velikanje Moore & CountrymanBlood containerUS3985135 *Mar 31, 1975Oct 12, 1976Baxter Laboratories, Inc.Dual chamber reservoirUS4379452 *Dec 6, 1979Apr 12, 1983Baxter Travenol Laboratories, Inc.Prepackaged, self-contained fluid circuit moduleUS4596657 *Jun 4, 1982Jun 24, 1986Miles Laboratories, Inc.Blood bag system with integral filtering meansUS4810378 *May 26, 1987Mar 7, 1989Miles Laboratories, Inc.Plastic blood bags joined by tubing and fiber filter; removal of white blood cellsUS4863452 *Feb 12, 1986Sep 5, 1989Minntech CorporationVenous reservoirUS4997577 *Dec 20, 1989Mar 5, 1991Baxter International Inc.Systems and methods for removing undesired matter from blood cellsUS5089146 *Feb 12, 1990Feb 18, 1992Miles Inc.Pre-storage filtration of plateletsUS5154716 *Nov 6, 1990Oct 13, 1992Miles Inc.Bottom blood bag separation systemEP0267286A1 *Mar 28, 1987May 18, 1988ASAHI MEDICAL Co., Ltd.Filter medium for selectively removing leucocytesEP0474267A2 *Aug 8, 1987Mar 11, 1992Asahi Kasei Kogyo Kabushiki KaishaA porous hollow fiber membrane and a method for the removal of a virus by using the sameEP0484751A1 *Oct 24, 1991May 13, 1992Pall CorporationBottom blood bag separation systemFR2305991A1 * Title not availableGB2238055A * Title not availableJPH0584071A * Title not availableJPH03123630A * Title not availableJPS6239636A * Title not availableWO1982001477A1 *Oct 23, 1981May 13, 1982Amf IncCharge modified microporous membrane,process for charge modifying said membrane and process for filtration of fluid* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS5783093 *Jan 2, 1997Jul 21, 1998Haemonetics CorporationAdding aqueous solution having specified limits of citrate,dextrose, adenine, and phosphate; concentratingUS5888408 *Nov 28, 1995Mar 30, 1999Heraeus Instruments Gmbh & Co. KgExpandable package with sterile interior-able to be transported and centrifugedUS5928214 *Aug 3, 1998Jul 27, 1999New York Blood Center, Inc.System for concentrating blood cellsUS6200287Sep 5, 1997Mar 13, 2001Gambro, Inc.Extracorporeal blood processing methods and apparatusUS6730055Mar 9, 2001May 4, 2004Gambro Inc.Separation; accumulation; using single needleUS6773413Dec 4, 2000Aug 10, 2004Gamero IncExtracorporeal blood processing methods and apparatusUS6945948Apr 20, 2004Sep 20, 2005Gambro, Inc.collection efficiency, reduce platelet activation of the apheresis system; collection of plasma and red blood cells may occur simultaneously or subsequently utilizing the same dual stage blood processing vesselUS7025877Jun 3, 1999Apr 11, 2006Baxter International Inc.Processing set for processing and treating a biological fluidUS7105093Oct 8, 2002Sep 12, 2006Baxter International Inc.Improved apparatus for light treatment of biological fluid that contains light activated photochemical agent for inactivating pathogens that may be present in biological fluid; bloodUS7169547May 15, 2001Jan 30, 2007New York Blood Center, Inc.Product from a high concentration of white blood cells with high cell viability; white blood cells are sequestered from the whole blood by preventing coagulation, separating the blood into two components, one rich in white blood cells; centrifugation, sequestering, then freezingUS7354415Apr 20, 2004Apr 8, 2008Gambro Bct, Inc.Extra-corporeal blood processing method and apparatus based on donor characteristicsUS7425304Feb 13, 2006Sep 16, 2008Fenwal, Inc.containers used for treating blood and blood components using ultraviolet radiation; contains photosensitizers and adsorber materials for removing excess photosensitizers and photoactivation by-productsUS7445756Oct 11, 2002Nov 4, 2008Fenwal, Inc.Treating biological fluid with light; connecting flexible container, tube; folding; disposable productsUS7699828Oct 13, 2005Apr 20, 2010Fenwal, Inc.Container for receiving a blood sampleUS7708710 *Apr 16, 2004May 4, 2010Fenwal, Inc.Method and apparatus for collecting and processing bloodUS8075468Feb 27, 2009Dec 13, 2011Fenwal, Inc.Systems and methods for mid-processing calculation of blood compositionUS8685258Feb 27, 2009Apr 1, 2014Fenwal, Inc.Systems and methods for conveying multiple blood components to a recipientUS8796017 *May 21, 2004Aug 5, 2014Jms Co., Ltd.Container for preparing serum and regenerative medical process using the same* Cited by examinerClassifications U.S. Classification210/782, 210/749, 422/40, 210/767, 210/789, 435/2, 604/6.15, 604/410, 422/1International ClassificationA61M1/02, A61M39/22Cooperative ClassificationA61M2039/222, A61M1/0209European ClassificationA61M1/02BLegal EventsDateCodeEventDescriptionNov 9, 2007FPAYFee paymentYear of fee payment: 12Nov 4, 2003FPAYFee paymentYear of fee payment: 8Nov 22, 1999FPAYFee paymentYear of fee payment: 4May 20, 1997CCCertificate of correctionMay 3, 1994ASAssignmentOwner name: TERUMO KABUSHIKI KAISHA, JAPANFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TANOKURA, NOBUKAZU;OHNAKA, YUKIHIRO;HOSONO, NORIO;AND OTHERS;REEL/FRAME:007001/0613;SIGNING DATES FROM 19940303 TO 19940314RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services©2012 Google